芪鹿消白方治疗2～3期慢性肾脏病的安全性和有效性的研究  

Safety and effectiveness of Qilu Xiaobai formula on chronic kidney disease patients at second to third stage with syndrome of spleen-kidney deficiency and phlegm-stasis obstructing collateral

作　　者：苏中昊[1] 杨雪军[2] 高建东[2] 王琛[2] 刘伟芳[2] 李迎巧 叶进[1] 

机构地区：[1]上海中医药大学基础医学院,上海201203 [2]上海中医药大学附属曙光医院

出　　处：《北京中医药大学学报》2015年第4期271-276,共6页Journal of Beijing University of Traditional Chinese Medicine

基　　金：2013年上海市大文科学术新人培育计划项目;2012年上海中医药大学中医临床基础学科建设课题(No.12ZLJ07);2014年上海中医药大学中青年骨干教师教学能力提升资助计划

摘　　要：目的 研究芪鹿消白方治疗2～3期慢性肾脏病脾肾亏虚、痰瘀痹络型患者的临床疗效。方法采用随机、对照的方法,将55例门诊患者分成2组,西药组18例、中药组37例。观察时间24周,2组患者均在常规基础治疗基础上,中药组加服芪鹿消白方,西药组加服氯沙坦。在治疗0、8、16、24周时,评价症状积分及证候积分,检测血清肌酐、尿素氮、24 h尿蛋白、肾小球滤过率。结果治疗前2组患者各项指标无明显差异（P〉0.05）。治疗后中药组证候积分明显低于西药组（P〈0.05）。慢性肾脏病常见症状（如腰酸乏力）在中药组得到明显改善（P〈0.05）。中药组治疗后血肌酐、尿素氮及24 h尿蛋白定量、肾小球滤过率均较治疗前有显著改善（P〈0.05）,而西药组无明显变化（P〉0.05）。结论 芪鹿消白方对2～3期慢性肾脏病脾肾亏虚、痰瘀痹络型患者在改善症状、降低证候积分值、保护肾功能方面显示了较好的临床疗效。Objective To study the effectiveness and safety of Qilu Xiaobai formula （ QLXB）, a Chinese herbal compound formulated by the TCM principle of invigorating spleen and restoring virility with dredging collateral and removing damp, on chronic kidney disease（CKD） patients at stage 2 - 3 with syn- drome of spleen-kidney deficiency and phlegm-stasis obstructing collateral. Methods 55 outpatients were divided randomly into Western medicinal group （n = 18） and QLXB group （n = 37）. All the patients in two groups were treated basic therapy, besides, those in Western medicinal group took orally losartan while QLXB group took QLXB formula for 24 weeks. At the time point of 0, 8, 16 and 24 week, score of symptoms and score of syndrome were calculated by completing a questionnaire, serum creatinine （Scr）, blood urea nitrogen（ BUN）, urinary protein in 24-hour（24UP） and glomerular filtration rate（ eGFR） were measured. Results There was no statistical difference of each index between two groups be fore treatment （P 〉 0. 05 ）. After treatment, symptom scores of QLXB group were significantly lower than those in the Western medicinal group （P 〈 0. 05 ）. The score of soreness of loins and fatigue was signifi- cantly decreased in QLXB group than that in Western medicinal group （ P 〈 0. 05 ）. The concentration of Scr,Bun,24 UP and eGFR was significantly lower in QLXB group than Western medicinal group （P 〈 0. 05）. Conclusion QLXB was safe and effective for treatment of CKD patients at stage 2 - 3.

关 键 词：芪鹿消白方 慢性肾脏病 安全性 有效性 

分 类 号：R256.51[医药卫生—中医内科学]